Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).
20 Fevereiro 2024 - 12:22PM
Edgar (US Regulatory)
| |
|
Fresenius Medical Care
AG
POB
61346 Bad Homburg
Germany
www.freseniusmedicalcare.com |
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 201549 |
|
February 20, 2024
| Re: | Notice of Disclosure Filed in Exchange Act Annual
Report Under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012
and Section 13(r) of the Exchange Act |
Ladies and Gentlemen:
Pursuant to Section 219
of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended,
notice is hereby provided that Fresenius Medical Care AG has made disclosure pursuant to such provisions in its Annual Report on Form
20-F for the fiscal year ended December 31, 2023, which was filed with the U.S. Securities and Exchange Commission on February 20, 2024.
Such disclosure begins on page 43 of the Annual Report on Form 20-F and is incorporated by reference herein.
Sincerely,
| By: |
/s/
Martin Fischer |
|
| Name: |
Martin Fischer |
|
| Title: |
Chief Financial Officer and member of the Management
Board |
|
Fresenius Medical Care AG, 61346 Bad Homburg, Germany, T +49 6172
609-0, Registered Office and
Commercial
Register: Hof (Saale), HRB 6841, VAT-ID No.: DE 811127677, Chair of Supervisory Board: Michael SenManagement Board: Helen Giza (Chair),
Martin Fischer, Franklin W. Maddux, Dr. Katarzyna Mazur-Hofsäß, Craig Cordola. Bank Account: Commerzbank AG, Frankfurt/Main,
IBAN: DE23 5008 0000 0711 6731 00, SWIFT/BIC: DRESDEFF501
Fresenius Medical Care (NYSE:FMS)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Fresenius Medical Care (NYSE:FMS)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
